Product Images Teriflunomide

This appears to be a table showing the results of a clinical trial for a drug called Teriflunomide. The table shows the number of participants at risk and the percentage of those who experienced disability progression sustained for 12 weeks. The drug was administered in three groups: placebo, 7mg Teriflunomide, and 14mg Teriflunomide. The results indicate that using 14mg Teriflunomide was significantly more effective than using the placebo (p < 0.05). However, the table is not clear and appears to have some formatting issues.*

This appears to be a table of data related to a 12-week clinical trial involving a placebo and two different doses of Teriflunomide. The table includes the percentage of sustained progression over 12 weeks for each group, as well as the number of participants at risk in each group. It is not possible to discern the full context or purpose of the study without additional information.*

Teriflunomide Tablets are a prescription drug provided in a pack of 30 tablets, each containing 14 mg of Terffunomide. It is distributed by Aurobindo Pharma USA, Inc. This medication should be stored at 20° to 25°C (68° to 77°F). Each patient should be given a separate Medication Guide. The suggested dose is one tablet taken orally once daily. This drug can be taken with or without food. The label includes a warning to keep it out of reach of children. The packaging includes printed information about the GTIN, Serial Number, Expiry Date, and LOT, that should be kept within the dotted line area of the package.*

This is a description of Teriflunomide tablets, its packaging, information on dosage, warnings and the name of the distributing company. Each tablet contains 14 mo of Terflunomide and usual dosage is one tablet a day. It can be taken with or without food. The tablets should be stored between 20 to 25 degrees Celsius. It is a prescription medicine and should be dispensed with a Medication Guide. The warning states that it should be kept out of reach of children.*